Eli Lilly and Company (NYSE:LLY) Stock Holdings Decreased by International Assets Investment Management LLC

International Assets Investment Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 99.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,519 shares of the company’s stock after selling 12,443,663 shares during the quarter. Eli Lilly and Company makes up approximately 0.7% of International Assets Investment Management LLC’s holdings, making the stock its 15th biggest holding. International Assets Investment Management LLC’s holdings in Eli Lilly and Company were worth $15,069,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of LLY. Lantz Financial LLC grew its position in shares of Eli Lilly and Company by 1.3% in the 2nd quarter. Lantz Financial LLC now owns 1,236 shares of the company’s stock worth $1,119,000 after acquiring an additional 16 shares in the last quarter. Private Management Group Inc. raised its holdings in shares of Eli Lilly and Company by 11.5% during the second quarter. Private Management Group Inc. now owns 649 shares of the company’s stock worth $588,000 after purchasing an additional 67 shares during the period. Cahill Financial Advisors Inc. bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $200,000. Liberty Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 20.9% in the 2nd quarter. Liberty Wealth Management LLC now owns 1,063 shares of the company’s stock valued at $963,000 after buying an additional 184 shares during the period. Finally, LGT Fund Management Co Ltd. grew its position in shares of Eli Lilly and Company by 89.4% during the 2nd quarter. LGT Fund Management Co Ltd. now owns 17,724 shares of the company’s stock valued at $16,047,000 after buying an additional 8,367 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Wolfe Research began coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Bank of America reissued a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,002.22.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $5.23 during trading hours on Wednesday, hitting $778.52. 645,591 shares of the company’s stock traded hands, compared to its average volume of 2,351,173. Eli Lilly and Company has a 52 week low of $612.70 and a 52 week high of $972.53. The company has a market cap of $739.06 billion, a price-to-earnings ratio of 84.16, a price-to-earnings-growth ratio of 2.99 and a beta of 0.41. The company’s fifty day simple moving average is $788.56 and its two-hundred day simple moving average is $861.70. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The business’s revenue was up 20.4% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 13.18 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 64.86%.

Eli Lilly and Company announced that its board has authorized a share buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.